Reportedly, the ongoing Covid-19 pandemic could cause a significant rise in the number of dementia patients in the long term, raised Alzheimer’s Disease International. The organization is urging the World Health Organization and governments around the world to “urgently fast track research on the potential impact of COVID-19 on increasing dementia rates.”
The research shows that pandemic could cause a significant rise in the number of dementia patients in the long term, as Covid infections can increase a person’s likelihood of developing dementia and cause dementia symptoms to show up earlier. Dementia is a condition with deterioration in the brain that impairs memory, behavior, thoughts, and emotion. Alzheimer’s disease is the most common form of dementia, and there is currently no cure for dementia.
In the short term, “dementia rates may drop temporarily as a result of the high number of deaths of people with dementia due to COVID-19, with between 25 to 45 percent of all COVID-19 deaths estimated to be of those with dementia,” the London-based group said in a media release.
But over the longer term, the number of people with dementia “could rise significantly due to the neurological impact of COVID-19,” it added.
The Alzheimer’s Disease International’s Medical and Scientific Advisory Panel, comprising of global experts on dementia, is studying the link between Covid-19 and Dementia, and how to deal with it. The chair of the advisory panel, Dr. Alireza Atri, raised that he is “particularly concerned” about the long-term effects of Covid, with symptoms like loss of smell and taste, “brain fog” and difficulties with memory, concentration.
Atri, who’s director of Banner Sun Health Research Institute in the U.S., also raised that Covid can damage and clot microvessels in the brain, hurt the body’s immunity and cause inflammation.
INmune Bio, Inc. (NASDAQ: INMB) is a publicly-traded clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and Treatment-Resistant Depression (XPro1595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate the minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors, and chronic inflammation.
Please visit the VP Watchlist Page for INmune Bio (INMB) at this link!
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, and receive our FREE email updates throughout the week and view our exclusive content and research.
